|
Match
|
Document |
Document Title |
|
|
US20090285887 |
Pharmaceutical Composition Comprising A Plurality of Mini-Tablets Comprising A Factor XA Inhibitor
A modified release pharmaceutical composition for oral administration comprising plural mini-tablets, comprising a therapeutically effective amount of a Factor Xa inhibitor within a matrix of...
|
|
|
US20090258066 |
COMPOSITIONS COMPRISING WEAKLY BASIC DRUGS AND CONTROLLED-RELEASE DOSAGE FORMS
The present invention is directed to pharmaceutical compositions, and methods of making such compositions, comprising microparticles containing a weakly basic drug core, a layer of alkaline buffer,...
|
|
|
US20090238867 |
Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
Nanoparticulate compositions comprising anidulafungin are described, as well as methods of making such compositions. Also described are methods for treatment of fungal infections.
|
|
|
US20090196924 |
CONTROLLED-RELEASE LAMOTRIGINE FORMULATIONS
Pharmaceutical controlled-release formulations comprising particles comprising lamotrigine or a pharmaceutically acceptable salt thereof, coated with a modified-release coating comprising a...
|
|
|
US20090191267 |
Oral Compositions Containing a Salivation Inducing Agent
Oral dosage forms, and particles used therein, containing salivation inducing agents are disclosed. The salivation agents may be in the core of the dosage form and/or in coatings applied thereto,...
|
|
|
US20090169617 |
Controlled Release Formulations Comprising Uncoated Discrete Unit(s) and an Extended Release Matrix
A controlled-release formulation comprising one or more distinct and discrete units located in physical juxtaposition to enable administration to a patient in need of treatment in a single dose,...
|
|
|
US20090123536 |
Oral Pharmaceutical Form of Losartan
The field of the present invention is that of oral pharmaceutical forms of losartan, and also treatments and administration methods relating thereto. The invention relates to the use, in an oral...
|
|
|
US20090028941 |
Pulsatile gastric retentive dosage forms
Dosage forms for delayed and pulsed release of therapeutic agents into the stomach are described. The dosage forms are gastric retentive dosage forms that achieve release of the therapeutic agent...
|
|
|
US20090011014 |
Tablet Formulation for Sustained Drug-Release
Disclosed is a pharmaceutical sustained release tablet for oral administration of a drug which is made of a compressed blend of at least three dry powders including a powder of a drug, a powder of...
|
|
|
US20080305161 |
INJECTABLE DEPOT FORMULATIONS AND METHODS FOR PROVIDING SUSTAINED RELEASE OF NANOPARTICLE COMPOSITIONS
Pharmaceutical formulations comprising: a compound selected from the group consisting of ziprasidone, having a maximum average particle size; a carrier; and preferably at least two surface...
|
|
|
US20080305160 |
Oral Medicament For The Modified Release Of At Least One Active Principle, In Multimicrocapsule Form
The field of the invention is that of oral medicaments or pharmaceutical compositions, in particular of the type including one or more active principles. The aim of the invention is to provide an...
|
|
|
US20080279937 |
CONTROLLED RELEASE POTASSIUM CHLORIDE TABLETS
A unit dosage form, such as a tablet for delivering potassium into the body in a controlled release fashion, comprises of a multiplicity of microencapsulated potassium chloride crystals, which are...
|
|
|
US20080260819 |
SUSTAINED RELEASE COMPOSITIONS OF DRUGS
A sustained release pharmaceutical composition has been developed. The composition resists dose dumping when broken, crushed or chewed, which enhances the safety of the dosage form should it be...
|
|
|
US20080254114 |
Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles
The present invention is directed to compositions comprising nanoparticulate heterocyclic amide derivative and preferably zafirlukast nanoparticles, also collectively referred to as “active...
|
|
|
US20080248113 |
ABUSE-PROOFED ORAL DOSAGE FORM
The present invention relates to an abuse-proofed, oral dosage form with controlled opioid-release for once daily administration, characterised in that it comprises at least one opioid with...
|
|
|
US20080206334 |
Pharmaceutical Polymer Composition For Oral Controlled-Release Delivery Of Terbutaline Sulfate
The present invention is directed to a controlled-release pharmaceutical composition providing a sustained delivery of the basic drug Terbutaline sulfate, said composition comprising at least...
|
|
|
US20080187588 |
Formulations With Controlled Release Of Active Ingredient
The present invention relates to novel pharmaceutical dosage forms with controlled release of active ingredient which comprise the PDE 5 inhibitor vardenafil and/or pharmaceutically acceptable...
|
|
|
US20080131492 |
Dosage forms for movement disorder treatment
The invention relates to the improvement in the treatment of certain neural disorders/diseases, such as Parkinson's disease and other motor disorders. One aspect of the invention relates to drug...
|
|
|
US20080118554 |
Pharmaceutical compositions comprising a combination of piperidinoalkanol and decongestant
A pharmaceutical composition comprising a first therapeutic agent and a second therapeutic agent is described. A plurality of particles comprising (i) an interior comprising the second therapeutic...
|
|
|
US20080085304 |
Robust sustained release formulations
Robust sustained release formulations, solid dosage forms comprising robust sustained release formulations, and methods for making and using these formulations and solid dosage forms are provided....
|
|
|
US20080044467 |
Formulation and process for drug loaded cores
The present invention relates to a controlled release pellet of metoprolol and its pharmaceutically acceptable salts that uses a water soluble or a water swellable inert starting seed or core.
|
|
|
US20080031947 |
Orally dissolvable/disintegrable lyophilized dosage forms containing protected
|